HIV testing in 2006: Issues and methods

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 4, 2006, Pages 565-582

  Chang, Denison ^a   Learmonth, Kate ^a   Dax, Elizabeth M ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

AIDS; Blood screening; HIV; HIV serodiagnosis; HIV tests; Immunoassays; Nucleic acid testing; Quality assurance; Simple rapid HIV tests; Testing accuracy; Testing strategies

Indexed keywords

CD4 ANTIGEN; DNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NUCLEIC ACID; RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGGLUTINATION TEST; ANTIBODY DETECTION; BLOOD ANALYSIS; BLOOD DONOR; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; CHEMOLUMINESCENCE; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; ENZYME IMMUNOASSAY; EPIDEMIC; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LABORATORY PERSONNEL; LABORATORY TEST; LYMPHOCYTE COUNT; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID ANALYSIS; OUTCOME ASSESSMENT; PATIENT COUNSELING; PATIENT SAFETY; PRACTICE GUIDELINE; PREVALENCE; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STAFF TRAINING; STANDARD; UNITED NATIONS; VIRUS IDENTIFICATION; VIRUS TRANSMISSION; WESTERN BLOTTING; WORLD HEALTH ORGANIZATION;

ANIMALS; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOASSAY; MASS SCREENING; POLYMERASE CHAIN REACTION; WORLD HEALTH ORGANIZATION;

EID: 33749534877     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.4.565     Document Type: Review

References (70)

1. Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220(4599), 868-871 (1983).
2. Dax EM, Arnott A. Advances in laboratory testing for HIV. Pathology 36(6), 551-560 (2004).
3. UNAIDS. 2004 Report on the Global AIDS Epidemic. (2004).
4. Ji G, Detels R, Wu Z, Yin Y. Correlates of HIV infection among former blood/plasma donors in rural China. AIDS 20(4), 585-591 (2006).
5. Mine H, Emura H, Miyamoto M et al. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J. Virol. Methods 112(1-2), 145-151 (2003).
6. Seed CR, Cheng A, Ismay SL et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 42(10), 1365-1372 (2002).
7. WHO, UNAIDS, CDC and USAIDS. Guidelines for using HIV testing technologies in surveillance: selection, evaluation and implementation. (2001).
8. Constantine NT, Saville RD, Dax EM. Chapter 10: Western blots, immunoblots, and line immunoassays. In: Retroviral Testing and Strategy: Essentials for Laboratory Diagnosis. Malloy Printers, MI, USA, 184-216 (2005).
9. WHO. Rapid HIV tests: guidelines for use in HIV testing and counselling services in resource-constrained settings. (2004).
10. Kanal K, Chou TL, Sovann L, Morikawa Y, Mukoyama Y, Kakimoto K. Evaluation of the proficiency of trained non-laboratory health staffs and laboratory technicians using a rapid and simple HIV antibody test. AIDS Res. Ther. 2(1), 5 (2005).
11. Tao G, Branson BM, Kassler WJ, Cohen RA. Rates of receiving HIV test results: data from the U.S. National Health Interview Survey for 1994 and 1995. J. Acquir. Immune Defic. Syndr, 22(4), 395-400 (1999).
12. Constantine NT, Saville RD, Dax EM. Chapter 5: rapid assays. In: Retroviral Testing and Quality Assurance: Essentials for Laboratory Diagnosis. Malloy Printers, MI, USA, 100-125 (2005)
13. Coates TJ, Grinstead OA, Gregorich SE et al. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. Lancet 356(9224), 103-112 (2000).
14. Morin SF, Khumalo-Sakutukwa G, Charlebois ED et al. Removing barriers to knowing HIV status: same-day mobile HIV testing in Zimbabwe. J. Acquir. Immune Defic. Syndr. 41(2), 218-224 (2006).
15. Perez F, Orne-Gliemann J, Mukotekwa T et al. Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe. Br. Med. J. 329(7475), 1147-1150 (2004).
16. WHO. Saving mothers, saving families: the MTCT-Plus Initiative. (2003).
17. Forsyth BW, Barringer SR, Walls TA et al. Rapid HIV testing of women in labor: too long a delay. J. Acquir. Immune Defic. Syndr. 35(2), 151-154 (2004).
18. UNAIDS/WHO. AIDS epidemic update: December 2004. (2004).
19. Makuwa M, Souquiere S, Niangui MT et al. Reliability of rapid diagnostic tests for HIV variant infection. J. Virol. Methods 103(2), 183-190 (2002).
20. WHO/UNAIDS. HIV assays: operational characteristics report 14/simple/ rapid tests. (2004).
21. Constantine NT, Saville RD, Dax EM. Chapter 16: nucleic acid tests for HIV. In: Retroviral Testing and Quality Assurance: Essentials for Laboratory Diagnosis. Malloy Printers, MI, USA, 288-324 (2005)
22. Ayele W, Baar MP, Goudsmit J et al. Surveillance technology for HIV-1 subtype C in Ethiopia: an env-based NASBA molecular beacon assay to discriminate between subcluster C and C'. J. Virol. Methods 130(1-2), 22-29 (2005).
23. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, John-Stewart GC. Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS 19(13), 1415-1422 (2005).
24. Emery S, Bodrug S, Richardson BA et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J. Clin. Microbiol 38(7), 2688-2695 (2000).
25. Elbeik T, Markowitz N, Nassos P et al. Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow. J. Clin. Microbiol. 42(7), 3120-3127 (2004).
26. Galli R, Merrick L, Friesenhahn M, Ziermann R. Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens.J. Clin. Virol. 34(4), 245-252 (2005).
27. Katsoulidou A, Petrodaskalaki M, Sypsa V et al. Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays - LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor vl.5. J, Virol. Methods 131(2), 168-174 (2006).
28. Roland ME, Elbeik TA, Kahn JO et al. HIV RNA testing in the context of nonoccupational postexposure prophylaxis. J. Infect. Dis. 190(3), 598-604 (2004).
29. Dunn DT, Brandt CD, Krivine A et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 9(9), F7-F11 (1995).
30. Lambert JS. Maternal-fetal transmission of HIV-1 infection. Pediatr. Ann. 22(7), 413-416 (1993).
31. Nesheim S, Palumbo P, Sullivan K et al. Quantitative RNA testing for diagnosis of HIV-infected infants. J. Acquir. Immune Defic. Syndr. 32(2), 192-195 (2003).
32. Candotti D, Temple J, Owusu-Ofori S, Allain JP. Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J. Virol Methods 118(1), 39-47 (2004).
33. Delwart EL, Kalmin ND, Jones TS et al. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang. 86(3), 171-177 (2004).
34. Quinn TC, Brookmeyer R, Kline R et al. Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS 14(17), 2751-2757 (2000).
35. + cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res. Hum. Retroviruses 16(7), 645-653 (2000).
36. Schmitt Y. Performance characteristics of quantification assays for human immunodeficiency virus type 1 RNA. J. Clin. Virol. 20(1-2), 31-33 (2001).
37. Staszewski S, DeMasi R, Hill AM, Dawson D. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS 12(15), 1991-1997 (1998).
38. Anastassopoulou CG, Touloumi G, Katsoulidou A et al. Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Virol. Methods 91(1), 67-74 (2001).
39. Yang Y, Lamendola MH, Mendoza M et al. Performance characteristics of the COBAS AmpliScreen HIV-1 test, version 1.5, an assay designed for screening plasma minipools. Transfusion 41(5), 643-651 (2001).
40. Constantine NT Zink H. HIV testing technologies after two decades of evolution. Indian J. Med. Res. 121(4), 519-538 (2005).
41. Desire N, Dehee A, Schneider V et al. Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J Clin. Microbiol. 39(4), 1303-1310 (2001).
42. Gibellini D, Vitone F, Schiavone P, Ponti C, La Placa M, Re MC. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique. J. Clin. Virol. 29(4), 282-289 (2004).
43. Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology. Nucleic Acids Res. 30(6), 1292-1305 (2002).
44. Yun Z, Fredriksson E, Sonnerborg A. Quantification of human immunodeficiency virus type 1 proviral DNA by the TaqMan real-time PCR assay. J. Clin. Microbiol. 40(10), 3883-3884 (2002).
45. Zhao Y, Yu M, Miller JW et al. Quantification of human immunodeficiency virus type 1 proviral DNA by using TaqMan technology. J. Clin. Microbiol. 40(2), 675-678 (2002).
46. Rouet F, Ekouevi DK, Chaix ML et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43 (6), 2709-2717 (2005).
47. Constantine NT, Saville RD, Dax EM. Chapter 15: HIV testing strategies and testing algorithms. In: Retroviral Testing and Quality Assurance: Essentials for Laboratory Diagnosis. Malloy Printers, MI, USA, 268-287 (2005).
48. Wilson KM, Johnson EI, Croom HA et al. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS 18(17), 2253-2259 (2004).
49. WHO. Blood safety and clinical technology: guidelines on standard operating procedures for microbiology. (Last updated 5th October, 2005).
50. Constantine NT, Saville RD, Dax EM. Chapter 22: Introduction to quality systems: quality management, quality assurance, quality control, quality assessment, continuous quality improvement. In: Retroviral Testing and Quality Assurance: Essentials for Laboratory Diagnosis. Malloy Printers, MI, USA (2005).
51. Rekart ML, Krajden M, Cook D et al. Problems with the fast-check HIV rapid test kits. CMAJ 167(2), 119 (2002).
52. Landrum ML, Wilson CH, Perri LP, Hannibal SL, O'Connell RJ. Usefulness of a rapid human immunodeficiency virus-1 antibody test for the management of occupational exposure to blood and body fluid. Infect. Control Hosp. Epidemiol. 26(9), 768-774 (2005).
53. Sherman GG, Jones SA. Oral fluid human immunodeficiency virus tests: improved access to diagnosis for infants in poorly resourced prevention of mother to child transmission programs. Pediatr. Infect. Dis. J. 24(3), 253-256 (2005).
54. Martinez P, Lejarazu RO, Eiros JM, Benito JD, Rodriguez-Torres A. Urine samples as a possible alternative to serum for human immunodeficiency virus antibody screening. Eur. J. Clin. Microbiol Infect. Dis. 15(10), 810-813 (1996).
55. Barletta JM, Edelman DC, Constantine NT. Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen. Am. J. Clin. Pathol. 122(1), 20-27 (2004).
56. Kallas EG, Bassichetto KC, Oliveira SM et al. Establishment of the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion (STARHS) strategy in the city of Sao Paulo, Brazil. Braz. J. Infect. Dis. 8(6), 399-406 (2004).
57. Respess RA, Rayfield MA, Dondero, TJ. Laboratory testing and rapid HIV assays: applications for HIV surveillance in hard-to-reach populations. AIDS 15(Suppl. 3), S49-S59 (2001).
58. Taylor MM, Hawkins K, Gonzalez A et al. Use of the serologic testing algorithm for recent HIV seroconversion (STARHS) to identify recently acquired HIV infections in men with early syphilis in Los Angeles County. J. Acquir. Immune Defic. Syndr 38(5), 505-508 (2005).
59. Parekh BS, Pau CP, Kennedy MS, Dobbs TL, McDougal JS. Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection. AIDS Res. Hum. Retroviruses 17(2), 137-146 (2001).
60. Rawal B D, Degula A, Lebedeva L et al. Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J. Acquir Immune Defic. Syndr. 33(3), 349-355 (2003).
61. Kothe D, Byers RH, Caudill SP et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J. Acquir. Immune Defic. Syndr. 33(5), 625-634 (2003).
62. Young CL, Hu DJ, Byers R et al. Evaluation of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res. Hum. Retroviruses 19(6), 481-486 (2003).
63. Dobbs T, Kennedy S, Pau CP. McDougal JS, Parekh BS. Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J. Clin. Microbiol. 42(6), 2623-2628 (2004).
64. Hu DJ, Vanichseni S, Mock PA et al. HIV type 1 incidence estimates by detection of recent infection from a cross-sectional sampling of injection drug users in Bangkok: use of the IgG capture BED enzyme immunoassay. AIDS Res. Hum. Retroviruses 19(9), 727-730 (2003).
65. Parekh BS, Kennedy MS, Dobbs T et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res. Hum. Retroviruses 18(4), 295-307 (2002).
66. Constantine NT, Ketema F. Rapid confirmation of HIV infection. Int. J. Infect. Dis. 6(3), 170-177 (2002).
67. Sommerfelt MA, Ohlsson I, Flolid I, Thorsterisson R, Sorensen B. A simple semi-rapid HIV-1&2 confirmatory immunoassay using magnetic particles. J. Virol. Methods 115(2), 191-198 (2004).
68. Bastian LA, Nanda K, Hasselblad V, Simel DL. Diagnostic efficiency of home pregnancy test kits. A meta-analysis. Arch. Fam. Med. 7(5), 465-469 (1998).
69. Ehrenkranz JR. Home and point-of-care pregnancy tests: a review of the technology. Epidemiology 13(3 Suppl.), S15-S18 (2002).
70. Church GM. Genomes for all. Sci. Am. 294(1), 46-54 (2006).